To review the efficacy and safety of phytotherapeutic compounds used to treat men with symptomatic benign prostatic hyperplasia (BPH).
How were the studies combined?
Studies evaluating Hypoxis rooperi were combined in a random-effects meta-analysis. Studies of the other treatments were combined narratively, grouped by intervention.
How were differences between studies investigated?
Differences between the studies in terms of interventions and comparators were discussed. Heterogeneity in the metaanalysis was assessed using a chi-squared test.
Results of the review
Four RCTs (n=519) evaluated Hypoxis rooperi, four RCTs (n=444) evaluated Secale cereale, five RCTs (n=543 and n=41; participant numbers not reported for three trials) evaluated Urtica dioica and one RCT (n=55) evaluated Curcubita pepo.
Hypoxis rooperi (4 RCTs).
Two studies that reported urinary symptom scores showed statistically significant improvements (WMD -4.91, 95% confidence interval, CI: -6.29, -3.53). Heterogeneity was not present in this result (P=0.49).
Four studies that reported peak urine flow showed a statistically significant improvement when pooled (WMD 3.91 mL/second, 95% CI: 0.91, 6.90). Significant heterogeneity was present in this result (P=0.00).
One trial showed no reduction in prostate size, while another trial showed no improvement in urinary flow rates. Adverse events were reported to be infrequent and mild. The withdrawal rates were reported to be similar to placebo.
Secale cereale (4 RCTs).
The authors reported that the studies could not be combined in a meta-analysis, owing to differences in the comparators and reporting methods. Data from all studies were reported to show improvement in symptoms and urinary flow. The only adverse event reported was mild nausea. Some methodological limitations were noted in the included studies.
Urtica dioica (5 RCTs).
Three of the included studies evaluated Urtica dioica combined with other phytotherapeutic agents; the results of two of these were not reported. One RCT, which compared a combined preparation of Sabal and Urtica with finasteride, found no differences between the groups in symptom scores, peak urine flow, or residual urine volume. More adverse events were associated with finasteride. Symptom scores were improved compared with placebo.
A small trial (n=41) found improvement in symptom scores compared with placebo. Another placebo-controlled trial reported improvements in peak urine flow and total voided volume, but no improvement in symptoms. This trial had a withdrawal rate of 24% in the Urtica group, half due to adverse effects.
Curcubita pepo (1 RCT).
In this trial Curcubita was combined with Sabal serrulata and compared with placebo. The treatment group reported improved self-rating of urinary symptoms and nocturia, and a greater reduction in urine volume than the placebo group.
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